schizophrenia (5) . In the first study, 37% of patients treated with olanzapine discontinued their medication at 12 months follow-up, owing to adverse events or lack of efficacy. In the second study, survival analysis at 6 months demonstrated that 27% and 32% of all patients treated with olanzapine or risperidone, respectively, discontinued their medication. In a naturalistic study, Binder and others reported that only 36.2% (21/58) schizophrenia and schizoaffective disorder patients were still on risperidone at 2-year follow-up (6) . Our own naturalistic study indicates that, among the individuals with schizophrenia or schizoaffective disorder treated with either olanzapine, risperidone, or clozapine at the time of their discharge from the hospital, 36%, 22%, and 8%, respectively, have discontinued their antipsychotic 1 year later (7) . The reasons for discontinuing were failure to achieve a therapeutic effect, noncompliance, and adverse side effects. Thus, one has to question the cost-effectiveness of some of the proposed laboratory monitoring with atypical antipsychotics. Diabetic ketoacidosis can occur in the first few months after initiating clozapine and olanzapine, and the prevalence and short-term health consequences justify regular monitoring of glycemia during the first year of treatment. By comparison, the immediate health consequences owing to weight gain and dyslipidemia are not a major concern in the first year of treatment, and monitoring of lipid parameters cannot be justified economically. However, clinicians should make patients aware of the risk of dyslipidemia with atypical antipsychotics, and preventive measures such as diet and physical exercise should be encouraged early in the treatment. 
Quetiapine May Induce Mania: A Case Report
Dear Editor:
Inducing manic or hypomanic symptoms is a well-documented risk during antidepressive treatment with different classes of antidepressants (1) (2) (3) .
Recently, several case reports and a critical review have demonstrated a similar risk induced by atypical antipsychotics, such as olanzapine and risperidone (4) . A serotonin (5-HT) receptor occupancy (5-HT 2 and 5-HT D2 ) hypothesis has been proposed to explain olanzapine and risperidone effects on mood (5) , but other mechanisms are likely involved in the manic switch that is associated with these 2 atypical antipsychotics (4).
A case report of a woman affected by schizoaffective disorder with quetiapine-associated hypomania has been published. She developed a hypomanic episode after 5 weeks of quetiapine treatment (gradually titrated to 300 mg daily), which receded in 1 week after quetiapine discontinuation (6) .
We report a further case of possible induction of manic episode associated with quetiapine treatment in a patient with a schizofreniform disorder.
Case Report
A 23-year-old woman with a DSM-IV diagnosis of schizofreniform disorder was hospitalized for a recent onset of psychotic symptoms, including anxiety, perplexity, and persecutory and somatic delusions. The patient had no history of substance abuse or manic or hypomanic episodes.
From the first day of hospitalization, a treatment with haloperidol 10 mg daily venlafaxine 75 mg daily, and diazepam 2 mg daily was started, but without improvement. Next, venlafaxine and haloperidol were discontinued, and a trial with quetiapine was started and titrated to 400 mg daily over 3 weeks. Gradually, her psychotic symptoms improved, but during the 4th week of treatment, insomnia, hyperactivity, irritability and hostility, elated mood, and grandiosity emerged.
Because of the suggestive temporal relation between the introduction of quetiapine and the onset of manic symptoms in a patient with no history of substance abuse or manic episodes, mania secondary to quetiapine was hypothesized. Quetiapine was discontinued and zuclopentixol and lorazepam were started. Manic symptoms gradually disappeared in the 10 days that followed and did not reappear during the 3-week hospitalization period.
We have described a possible case of mania induced by quetiapine in a patient with schizofreniform disorder. The gradual onset of manic symptoms during quetiapine treatment and the rapid remission with discontinuation of the drug in a patient without a history of mania and without past or current substance abuse seems to support the possibility that quetiapine was responsible for inducing the manic episode. In our case, which is similar to Benazzi's case, manic symptoms appeared slowly at a moderate quetiapine dosage (6) . This seems to support the hypothesis proposed for risperidone, with which quetiapine shares biochemical features; specifically, at high dosages, dopaminergic blockade action shows antimanic properties, while, conversely, at smaller dosages, the mania-inducing effects could result from the 5-HT 2 antagonistic action, as well as the ensuing dopamine disinhibiting effects (5) .
Although further observations are necessary, clinicians should be aware that quetiapine (as olanzapine and risperidone) may play a role in inducing mania. 
Insight, Knowledge, and Beliefs About Illness in First-Episode Psychosis

Dear Editor:
Psychoeducation about psychosis is a valuable therapeutic strategy in that it may improve understanding of the illness itself and potentially modify patients' behaviours and attitudes (1) . In our comprehensive Early Psychosis Program (EPP), we offer education about the illness in family intervention sessions and through case and psychiatric management with a specifically designed Psychosis Education Group (2) . We describe here a study that explored the impact of providing education about psychosis to individuals experiencing a first episode of a psychotic illness. Of the 78 subjects, 57 were men and 21 were women (mean age 24.7 years). They had been attending EPP as outpatients for between 12 and 30 months and had either full or partial remission of positive symptoms. We designed a multiple-choice questionnaire (the Knowledge About Psychosis Questionnaire) based on existing knowledge questionnaires in the literature and on the material taught in our program (3). We used the Insight Scale (4) to obtain information on insight regarding psychiatric illness (that is, attribution of symptoms, awareness of illness, and need for treatment). We administered the Personal Beliefs About Illness Questionnaire (PBIQ) (5) to obtain patients' current beliefs about their illness and the degree to which patients felt that the social and scientific beliefs about their illness reflect statements about themselves. The PBIQ assesses beliefs about control over the psychotic illness; about the perception of the self as illness; and about expectations, stigma, and social containment. Both scales have good test-retest reliability and validity (4, 5) .
Overall, individual patients were knowledgeable about their illness: 90% answered correctly on at least 75% of the items. Good knowledge was significantly associated with good insight about the psychotic illness (P < 0.05). However, having good knowledge about the facts of the illness was not related to individuals' beliefs about the illness. Further, those who demonstrated good insight did not necessarily demonstrate positive beliefs about the illness. Pearson correlational analyses revealed that those demonstrating good insight endorsed items on the PBIQ that suggested lack of control over the illness (P < 0.001), expectations of requiring care for the illness (P < 0.01), experiences of stigma (P < 0.05), and the need for social containment (P < 0.05).
These data imply that offering education to individuals with psychosis, even when they demonstrate good insight into the illness, may not be enough. Rather, these data support the need to understand and address the beliefs individuals hold about their psychosis-beliefs that tend to reflect negative statements about themselves. Such beliefs may lead to secondary morbidity following illness onset. Recent support for cognitive-behavioural therapy (CBT) with first-episode subjects (6) implies that CBT may be an appropriate intervention to help challenge some of the personal beliefs that may impact negatively on outcome.
Laura Quillams, BA Calgary, Alberta Jean Addington, PhD Toronto, Ontario
The Symptoms of Atypical Depression
Studies of the diagnostic criteria of atypical depression have recently increased. In one such study, Parker and others sampled individuals with major depressive disorder (MDD) (1) and, after finding weak correlations and associations among only some atypical symptoms, reported weak support for DSM-IV-TR atypical features criteria (2) . (According to these criteria, an individual must present a bipolar or MDD major depressive episode or dysthymic disorder, always including mood reactivity plus at least 2 of the following: increased weight or appetite, hypersomnia, significant energy loss, and long-standing sensitivity to interpersonal rejection, but no melancholic or catatonic features.) In another study, Posternak and Zimmerman found no correlations among atypical symptoms in subjects who mainly suffered from MDD (3). An
